SALVATORELLI, EMANUELA
SALVATORELLI, EMANUELA
Facoltà Dipartimentale di Medicina e Chirurgia
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes
2009-01-01 Menna, P; Salvatorelli, E; Minotti, G
Anthracycline Cardiotoxicity
2008-01-01 Menna, P.; Salvatorelli, E.; Gianni, L.; Minotti, G
Anthracycline Cardiotoxicity
2012-01-01 Menna, P; Gonzalez Paz, O; Chello, M; Covino, E; Salvatorelli, E; Minotti, G
Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes
2007-01-01 Gianni, L; Salvatorelli, E; Minotti, G
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival
2010-01-01 Menna, P; Salvatorelli, E; Minotti, G
Anthracyclines
2008-01-01 Minotti, G; Salvatorelli, E; Menna, P
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker?
2023-01-01 Minotti, Giorgio; Salvatorelli, Emanuela; Menna, Pierantonio
Anthracyclines, diastolic dysfunction and the road to heart failure in Cancer survivors: An untold story
2024-01-01 Camilli, Massimiliano; Ferdinandy, Péter; Salvatorelli, Emanuela; Menna, Pierantonio; Minotti, Giorgio
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity
2004-01-01 Minotti, G; Menna, P; Salvatorelli, E; Cairo, G; Gianni, L.
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology
2022-01-01 Minotti, Giorgio; Menna, Pierantonio; Camilli, Massimiliano; Salvatorelli, Emanuela; Levi, Roberto
Cancer drugs and QT prolongation: weighing risk against benefit
2017-01-01 Menna, P.; Salvatorelli, E; Minotti, G.
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION
2022-01-01 Minotti, Giorgio; Salvatorelli, Emanuela; Reggiardo, Giorgio; Mangiacapra, Fabio; Camilli, Massimiliano; Menna, Pierantonio
Cardiotoxicity of antitumor drugs
2008-01-01 Menna, P; Salvatorelli, E; Minotti, G
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab
2019-01-01 Menna, P; Minotti, G; Salvatorelli, E.
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues.
2011-01-01 Cacciapaglia F, F.; Navarini, L.; Menna, P.; Salvatorelli, E.; Minotti, G; Afeltra, A.
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts
2010-01-01 Menna, P.; Salvatorelli, E.; Salsano, C.; Gianni, L.; Minotti, G.
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life
2021-01-01 Menna, P; Salvatorelli, E; Del Principe, Mi; Perrone, S; Pagano, L; Marchesi, F; Minotti, G.
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity
2003-01-01 Sacco, G.; Giampietro, R.; Salvatorelli, E.; Menna, P; Bertani, N.; Graiani, G.; Animati, F.; Goso, C.; Maggi, C. A.; Mancinis, S.; Minotti, G.
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition
2006-01-01 Salvatorelli, E; Guarnieri, S; Menna, P; Liberi, G; Calafiore, Am; Mariggio, Ma; Mordente, A; Gianni, L; Minotti, G
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies
2007-01-01 Salvatorelli, E.; Menna, P.; Gianni, L.; Minotti, G